Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Nervous System Neoplasms » Central Nervous System Neoplasms » Brain Neoplasms
Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Brain Diseases » Brain Neoplasms
Diseases [C] » Nervous System Diseases [C10] » Nervous System Neoplasms » Central Nervous System Neoplasms » Brain Neoplasms
Description
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. MeSH
Hierarchy View
Subtype Terms (5)
Infratentorial Neoplasms
6 drugs (5 approved, 1 experimental)
Neurocytoma
2 approved drugs
Pinealoma
26 drugs (19 approved, 7 experimental)
Supratentorial Neoplasms
11 drugs (7 approved, 4 experimental)
Approved Indicated Drugs (3)
Phase 4 Indicated Drugs (28)
Phase 2 Indicated Drugs (179)
2-(5-fluoro-pentyl)-2-methyl-malonic-acid
4-demethyl-4-cholesteryloxycarbonylpenclomedine
anti-her2/her3 dendritic cell vaccine
antineoplaston AS2-1 (astugenal)
Phase 1 Indicated Drugs (174)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous dendritic cells loaded with autologous tumor lysate
dec-205/ny-eso-1 fusion protein cdx-1401
demeclocycline hydrochloride (declomycin)
dendritic vaccine pulsed with glioma peptides
e. coli cd-expressing genetically modified neural stem cells
genetically-modified neural stem cells expressing e.coli cytosine deaminase
Other Experimental Indicated Drugs (30)
Organization Involved with Phase 4 Indications (26)
Organization Involved with Phase 3 Indications (45)
Organization Involved with Phase 2 Indications (182)
Assistance Publique - Hôpitaux de Paris
Australia and New Zealand Melanoma Trials Group
Beijing Tricision Biotherapeutics Inc
BioMimetix Pharmaceutical, Inc.
BioNumerik Pharmaceuticals, Inc.
British Columbia Cancer Agency
Case Western Reserve University
Collaborative Ependymoma Research Network
First People's Hospital of Hangzhou
Florida Cancer Specialists, Sarasota
Florida International University
Grupo Español de Investigación en Neurooncología (GEINO)
Grupo Español Multidisciplinar de Melanoma
Guangdong Association of Clinical Trials
Guangzhou Trinomab Biotech Co., Ltd.
Hellenic Cooperative Oncology Group
Hoosier Cancer Research Network
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Kliniken Nordoberpfalz AG Klinikum Weiden Medizinische Kliniken I
Methodist Cancer Center, Houston, Texas
National Comprehensive Cancer Network
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health (NIH)
National Natural Science Foundation of China
North Central Cancer Treatment Group
Online Collaborative Oncology Group
Oregon Health and Science University
Radiation Therapy Oncology Group
Second Military Medical University
Shanghai Armed Police Hospital
The First People's Hospital of Lianyungang
The University of Texas, Dallas
Universidad Complutense de Madrid
University of Alabama, Birmingham
University of California, Davis
University of California, San Diego
University of North Carolina at Chapel Hill
Virginia Commonwealth University
Organization Involved with Phase 1 Indications (61)
Annias Immunotherapeutics, Inc.
Breast Cancer Research Foundation
Children's Cancer and Leukaemia Group
Children's National Medical Center
Organization Involved with Other Experimental Indications (13)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
